EVI5L

Across TCGA pan-cancer cohorts, EVI5L RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of EVI5L’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where EVI5L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EVI5L is over-expressed in tumor, although a few such as KIRC and READ show the opposite, repressed pattern.

LIHC, KIRC, and KICH are the cancer types where EVI5L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EVI5L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.304	<.001	9	view →
KIRC	Male	II,III,IV	−0.654	<.001	9	view →
KICH	Female	II,III,IV	+1.252	<.001	8	view →
HNSC	Female	II,III,IV	+0.472	<.001	8	view →
READ	All	All	−0.583	.006	6	view →
BRCA	All	All	+0.281	<.001	6	view →
CHOL	All	All	+1.394	<.001	3	view →
BLCA	Male	IV	−0.830	.027	2	view →
KIRP	Male	All	−0.396	.004	2	view →
LUAD	Male	All	−0.387	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

EVI5L–LIHC

Open the LIHC breakdown →